arrow_back Back to App

Emergency Insulin Access, Price Control, and Reduced Drug Exclusivity

This Act establishes state-level Insulin Assistance Programs to provide no-cost insulin access to uninsured and underinsured individuals. It introduces financial penalties (excise tax) on manufacturers who implement price hikes above inflation that are not justified by production costs. Furthermore, it reduces the market exclusivity period for biological products from 12 to 7 years.
Key points
Uninsured and underinsured individuals can receive insulin at no cost through state-issued insulin cards.
For those with high-deductible plans, payments made by the assistance program for insulin must count toward their annual deductible and out-of-pocket maximums.
Insulin manufacturers face a new excise tax if they raise prices significantly faster than the rate of inflation (price spike).
The market exclusivity period for biological products is shortened from 12 years to 7 years.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_S_1497
Sponsor: Sen. Smith, Tina [D-MN]
Process start date: 2023-05-09
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-3-pro-preview
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Emergency Access to Insulin Act of 2023

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_S_1497.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2023-05-09.

What are the main provisions?

Key points include:

  • Uninsured and underinsured individuals can receive insulin at no cost through state-issued insulin cards.
  • For those with high-deductible plans, payments made by the assistance program for insulin must count toward their annual deductible and out-of-pocket maximums.
  • Insulin manufacturers face a new excise tax if they raise prices significantly faster than the rate of inflation (price spike).
  • The market exclusivity period for biological products is shortened from 12 years to 7 years.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Smith, Tina [D-MN].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-30.

CATEGORIES

Health Economy Benefits